400 related articles for article (PubMed ID: 21048966)
21. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor.
Hong MY; Seeram NP; Heber D
J Nutr Biochem; 2008 Dec; 19(12):848-55. PubMed ID: 18479901
[TBL] [Abstract][Full Text] [Related]
22. Tissue-selective regulation of androgen-responsive genes.
Otto-Duessel M; He M; Jones JO
Endocr Res; 2012; 37(4):203-15. PubMed ID: 22591338
[TBL] [Abstract][Full Text] [Related]
23. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
24. Effects of perinatal exposure to flutamide on sex hormone responsiveness in F1 male rats.
Miyata K; Yabushita S; Sano M; Miyashita K; Okuno Y; Matsuo M
J Toxicol Sci; 2003 Aug; 28(3):149-63. PubMed ID: 12974607
[TBL] [Abstract][Full Text] [Related]
25. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.
D'Antonio JM; Vander Griend DJ; Antony L; Ndikuyeze G; Dalrymple SL; Koochekpour S; Isaacs JT
PLoS One; 2010 Jul; 5(7):e11475. PubMed ID: 20628607
[TBL] [Abstract][Full Text] [Related]
26. Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCaP prostate cancer cells.
Cha S; Shin DH; Seok JR; Myung JK
Exp Cell Res; 2017 Oct; 359(1):215-225. PubMed ID: 28736082
[TBL] [Abstract][Full Text] [Related]
27. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.
Tanner MJ; Welliver RC; Chen M; Shtutman M; Godoy A; Smith G; Mian BM; Buttyan R
PLoS One; 2011 Jan; 6(1):e16027. PubMed ID: 21267466
[TBL] [Abstract][Full Text] [Related]
28. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells.
Gerdes MJ; Dang TD; Larsen M; Rowley DR
Endocrinology; 1998 Aug; 139(8):3569-77. PubMed ID: 9681509
[TBL] [Abstract][Full Text] [Related]
30. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer.
Mo W; Zhang J; Li X; Meng D; Gao Y; Yang S; Wan X; Zhou C; Guo F; Huang Y; Amente S; Avvedimento EV; Xie Y; Li Y
PLoS One; 2013; 8(2):e56592. PubMed ID: 23451058
[TBL] [Abstract][Full Text] [Related]
32. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
33. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of clusterin and its isoforms by androgens in prostate cells.
Cochrane DR; Wang Z; Muramaki M; Gleave ME; Nelson CC
J Biol Chem; 2007 Jan; 282(4):2278-87. PubMed ID: 17148459
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher CE; Sulpice E; Combe S; Shibakawa A; Leach DA; Hamilton MP; Chrysostomou SL; Sharp A; Welti J; Yuan W; Dart DA; Knight E; Ning J; Francis JC; Kounatidou EE; Gaughan L; Swain A; Lupold SE; de Bono JS; McGuire SE; Gidrol X; Bevan CL
Oncogene; 2019 Jul; 38(28):5700-5724. PubMed ID: 31043708
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
37. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
38. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of PLZF as a prostatic androgen-responsive gene.
Jiang F; Wang Z
Prostate; 2004 Jun; 59(4):426-35. PubMed ID: 15065091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
